View Exam | PowerPak

1. MW is a 62-year-old male (BMI 37 kg/m²) who is admitted to the hospital with a COPD exacerbation secondary to community-acquired pneumonia. His other past medical history includes type 2 diabetes mellitus, hypertension, and a current smoker with a 50-pack-year history. He is on appropriate medications for these conditions. His labs are within normal limits and his vital signs are stable except for tachypnea and elevated temperature. MW is initiated on his home medications as well as IV ceftriaxone, methylprednisolone, and albuterol nebulization.

How many risk factors does MW have for developing a venous thromboembolism?

A. 2 B. 3 C. 4 D. 5 E. 6 F. Unsure

2. What factor does MW have, in addition to the typical medically ill patient that would make him eligible for extended VTE prophylaxis?

A. BMI ≥ 35 kg/m² B. Smoking C. Infectious process contributing to admission D. A and C are correct E. All of the above are correct F. Unsure

3. Which of the following agents would be appropriate for MW to receive for extended VTE prophylaxis?

A. Enoxaparin B. Rivaroxaban C. Apixaban D. Edoxaban E. Unfractionated heparin F. Unsure

4. Which of the following national organizations support the use of extended prophylaxis in medically ill patients?

A. North American Thrombosis Forum (NATF) B. American College of Chest Physicians (ACCP) C. Anticoagulation Forum (AC Forum) D. A and C are correct E. All of the above are correct F. Unsure

5. MW would like to know the benefits and risks of extended VTE prophylaxis with rivaroxaban. Which of the following would be the counseling message for MW?

A. Rivaroxaban significantly reduces the risk of VTE without increasing the risk of major bleeding B. Rivaroxaban significantly reduces the risk of VTE and major bleeding C. Rivaroxaban does not reduce the risk of VTE or increase risk of major bleeding D. Rivaroxaban does not reduce the risk of VTE and increases the risk of major bleeding E. Rivaroxaban significantly reduces the risk of VTE and increases the risk of major bleeding F. Unsure

6. Which of the following represents an appropriate strategy to optimize the transition of care from the hospital to home with extended VTE prophylaxis?

A. Use meds-to-beds B. Reconcile the discharge plan with national guidelines C. Assess the patient's understanding of the discharge plan D. Educate patients on management of bleeding E. All of the above are correct F. Unsure

7. Which of the following educational messages is important for a patient receiving extended VTE prophylaxis?

A. How to watch for bleeding events B. How to administer a subcutaneous injection C. Importance of preventing VTE D. A and C are correct E. All of the above are correct F. Unsure

8. When educating the patient, how long will they need to receive extended VTE prophylaxis?

A. 10 days B. 30 days C. 60 days D. 90 days E. 180 days F. Unsure

9. A physician says he would like to use apixaban for extended VTE prophylaxis. Which of the following represents the findings of the ADOPT trial with apixaban for extended prophylaxis in medically ill patients?

A. Apixaban significantly reduces the risk of VTE without increasing the risk of major bleeding B. Apixaban significantly reduces the risk of VTE and major bleeding C. Apixaban does not reduce the risk of VTE or increase risk of major bleeding D. Apixaban does not reduce the risk of VTE and increases the risk of major bleeding E. Apixaban significantly reduces the risk of VTE and increases the risk of major bleeding F. Unsure

10. What role does the pharmacist play in helping to optimize transition of care for patients receiving extended prophylaxis?

A. Telephone follow up within 2 to 4 days B. Plan for follow-up of lab tests or studies pending at discharge C. Ensure the patient understands importance of adherence D. A and C are correct E. All of the above are correct F. Unsure

Evaluation Questions

11. How confident are in your treatment choice for MW in the questions above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. What factor does MW have, in addition to the typical medically ill patient that would make him eligible for extended VTE prophylaxis?

3. Which of the following agents would be appropriate for MW to receive for extended VTE prophylaxis?

4. Which of the following national organizations support the use of extended prophylaxis in medically ill patients?

5. MW would like to know the benefits and risks of extended VTE prophylaxis with rivaroxaban. Which of the following would be the counseling message for MW?

6. Which of the following represents an appropriate strategy to optimize the transition of care from the hospital to home with extended VTE prophylaxis?

7. Which of the following educational messages is important for a patient receiving extended VTE prophylaxis?

8. When educating the patient, how long will they need to receive extended VTE prophylaxis?

9. A physician says he would like to use apixaban for extended VTE prophylaxis. Which of the following represents the findings of the ADOPT trial with apixaban for extended prophylaxis in medically ill patients?

10. What role does the pharmacist play in helping to optimize transition of care for patients receiving extended prophylaxis?

Evaluation Questions

11. How confident are in your treatment choice for MW in the questions above?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. What factor does MW have, in addition to the typical medically ill patient that would make him eligible for extended VTE prophylaxis?

3. Which of the following agents would be appropriate for MW to receive for extended VTE prophylaxis?

4. Which of the following national organizations support the use of extended prophylaxis in medically ill patients?

5. MW would like to know the benefits and risks of extended VTE prophylaxis with rivaroxaban. Which of the following would be the counseling message for MW?

6. Which of the following represents an appropriate strategy to optimize the transition of care from the hospital to home with extended VTE prophylaxis?

7. Which of the following educational messages is important for a patient receiving extended VTE prophylaxis?

8. When educating the patient, how long will they need to receive extended VTE prophylaxis?

9. A physician says he would like to use apixaban for extended VTE prophylaxis. Which of the following represents the findings of the ADOPT trial with apixaban for extended prophylaxis in medically ill patients?

10. What role does the pharmacist play in helping to optimize transition of care for patients receiving extended prophylaxis?

Evaluation Questions

11. How confident are in your treatment choice for MW in the questions above?

« Return to Activity

Customers who Purchased
this Activity also Purchased